The Global Hepatitis Therapeutic market was valued at $ 23.4 Billion in 2017 and is forecast to grow at a modest 3.6 % CAGR between 2018 and 2025, culminating in 2025 global sales of $ 27.8 Billion. Rising viral infection including type A, B, C, D, E and possible G are major cause of hepatitis. Hepatis B and C can cause chronic hepatitis. Symptoms of acute hepatitis A include fatigue, flu like conditions or dark urine where as chronic hepatitis are mild and non-specific.
As per Center for Disease Control (CDC), in 2017 reported cases of hepatitis C nearly tripled, reaching 15 years high. Actually 10 times more patients get undetected. Similarly, 1,390 new patients reported with Hepatitis A and 3,370 new cases of Hepatitis B in 2015. We are observing steep rise in cases of hepatitis C in particular in last few years and trend is going to continue. Patients with autoimmune disorder are adding to increase prevalence of hepatitis. Aging population and changing societal behavior adding to this steady increase. Globally, in 2015, an estimated 257 million people were living with chronic HBV infection, and 71 million people with chronic HCV infection.
We are observing increasing deaths due to viral hepatitis globally, 1.34 million deaths in 2015, comparable to deaths caused by tuberculosis and higher than those caused by HIV. However, the number of deaths due to viral hepatitis is increasing over time, while mortality caused by tuberculosis and HIV is declining.
“Optimal Price Point (OPP) for Global Hepatitis Therapeutics Products”
Estimated Average Hepatitis Therapeutics product cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.
Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the world, the Hepatitis Therapeutics products are available at USD XXXX. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.
Hepatitis A- It’s a short-term illness and may not require any medication apart from bed rest and physician order for hydration and nutrition. Hepatitis A vaccine is also available to prevent infection.
Hepatitis B- It’s treated with antiviral medications. These treatments are supposed to continue for several months. It also requires regular physician supervision to ensure if the virus is responding to the treatment. Hepatitis B vaccination available recommended for all newborns.
Hepatitis C- Antiviral medications are usually recommended for the treatment of hepatitis C. Currently there is no vaccination for Hepatitis C.
Hepatitis D- No antiviral medications for the treatment of hepatitis D. Limited improvement noticed with fewer patients with a drug called alpha interferon. It can also prevent by vaccination for Hepatitis B.
Hepatitis E- No specific medication for hepatitis E apart from sufficient rest, water and nutrients.
Some of the U.S. FDA recommended antiviral medicines for the treatment of hepatitis B are as below-
Some of the U.S. FDA recommended antiviral medicines for the treatment of hepatitis C are as below-
We have segmented the market based on the type of hepatitis as Hepatitis A, B, C, D, E, and others.
We have segmented the market based on medications and vaccines. We will help our client in understanding market segment for individual treatment type if necessary at a premium service.
North America accounted for over xx% revenue share in 2017. The key reasons attributed to the high share include strong reimbursement framework, technological advancements and government support for R&D and innovation in medical devices sector. Moreover, the presence of high-end hospital and POC and high emphasis on prevention is expected to boost the usage rates over the forecast period.
Asia Pacific is expected to register the maximum CAGR of xx% from 2017 to 2025. The rapid increase in a number of chronic cases, growing healthcare expenditure and skill training, and improvement in reimbursement scenario are expected to favor the high market growth in the region.
Top Players & Company Share
We have profiled major players in the market as Sanofi, GSK, Merck & Co., Roche, Bristol-Myers Squibb Company, Gilead, Vertex Pharmaceuticals, Three Rivers Pharma, Schering, Janssen Pharmaceuticals, Schering, Gilead Sciences, Merck Sharp Dohme. With recent development, we are observing some unique new players into the market.
Global Hepatitis Therapeutics Market by Disease Types (Revenue, USD Million, 2014- 2025)
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
Global Hepatitis Therapeutics Market by Products (Revenue, USD Million, 2014 – 2025)
Global Hepatitis Therapeutics Systems Regional Outlook (Revenue, USD Million, 2014- 2025)
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa